Well, yeah - in nulls after 14 days (arguably one of the breakthroughs could have been noticed at day 14 - but regardless VRUS abstract didn't give equivalent data on breakthroughs or viral load measurements). Has the VRUS drug combo been run in that environment (more than 14 days? In nulls)? Also note that I know of no BMY trial which is a three DAA combo - did I miss something?
So you are assuming both that if you add a 3rd DAA you can both improve SVR and(!!!) shorten duration of treatment. That seems a leap too far to me.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.